Emcure Pharmaceuticals Limited has informed the Exchange about Action(s) initiated or orders passed
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts less than Nifty Smallcap 250 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Emcure Pharmaceuticals has disclosed a regulatory order received on June 24, 2025, from the Regional Director (Western Region), Ministry of Corporate Affairs, regarding the compounding of an alleged violation of Section 152 of the Companies Act, 2013. The issue relates to the company's 2015 and 2016 Annual General Meetings, where two directors were due to retire by rotation each year, but only one director retired in each of those AGMs. The Regional Director compounded the offence and imposed a total compounding fee of Rs. 1,75,000 (Rs. 87,500 each for two applicant directors, including one ex-director). The directors have already paid the fees from their own funds, and the compounding application now stands disposed of.
This is a minor, historical compliance matter that has been fully settled with negligible financial impact. The fees were paid personally by the directors and the company has confirmed no material impact on its financials or operations, so investors should not expect any meaningful effect on the stock.